Obecabtagene autoleucel治疗成人B细胞急性淋巴细胞白血病
这项1b-2期多中心研究报告,obecabtagene autoleucel(obe-cel)用于成人复发或难治性B细胞急性淋巴细胞白血病,队列2A(94例)总缓解率77%(95%CI 67-85),完全缓解率55%(95%CI 45-66);127例输注者中位无事件生存期11.9个月,中位总生存期15.6个月,3级及以上细胞因子释放综合征2.4%、3级及以上免疫效应细胞相关神经毒性综合征7.1%。
要点
- 队列2A总缓解率77%,完全缓解率55%,完全缓解伴血液学不完全恢复21%。
- 127例输注者中位无事件生存期11.9个月,中位总生存期15.6个月。
- 3级及以上细胞因子释放综合征2.4%,3级及以上免疫效应细胞相关神经毒性综合征7.1%。
核心结论
- obe-cel在成人复发或难治性B细胞急性淋巴细胞白血病中产生高比例的持久缓解,且3级及以上免疫相关毒性发生率低。
研究设计与样本
- 1b-2期多中心研究,纳入年龄≥18岁的复发或难治性B细胞急性淋巴细胞白血病成人患者。
- 主要队列2A纳入形态学疾病患者,队列2B纳入可测量残留病患者;主要终点为队列2A的总缓解(完全缓解或完全缓解伴血液学不完全恢复)。
- 153例入组患者中127例(83.0%)接受至少一次obe-cel输注并可评估。
主要发现
- 队列2A(94例;中位随访20.3个月)总缓解率为77%(95%CI 67-85),完全缓解55%(95%CI 45-66),完全缓解伴血液学不完全恢复21%(95%CI 14-31)。
- 预设无效假设总缓解≤40%和完全缓解≤20%被拒绝(P<0.001)。
- 127例接受至少一次输注患者(中位随访21.5个月)中位无事件生存期11.9个月(95%CI 8.0-22.1),估计6个月和12个月无事件生存率分别为65.4%和49.5%。
- 中位总生存期15.6个月(95%CI 12.9-不可评估),估计6个月和12个月总生存率分别为80.3%和61.1%。
- 3级及以上细胞因子释放综合征发生于2.4%的患者,3级及以上免疫效应细胞相关神经毒性综合征发生于7.1%的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. METHODS: We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients with morphologic disease; patients in cohort 2B had measurable residual disease. The primary end point was overall remission (complete remission or complete remission with incomplete hematologic recovery) in cohort 2A. Secondary end points included event-free survival, overall survival, and safety. RESULTS: Of the 153 enrolled patients, 127 (83.0%) received at least one infusion of obe-cel and were evaluable. In cohort 2A (94 patients; median follow-up, 20.3 months), overall remission occurred in 77% (95% confidence interval [CI], 67 to 85), with complete remission in 55% (95% CI, 45 to 66) and complete remission with incomplete hematologic recovery in 21% (95% CI, 14 to 31). The prespecified null hypotheses of overall remission (≤40%) and complete remission (≤20%) were rejected (P<0.001). In the 127 patients who received at least one obe-cel infusion (median follow-up, 21.5 months), the median event-free survival was 11.9 months (95% CI, 8.0 to 22.1); estimated 6- and 12-month event-free survival was 65.4% and 49.5%, respectively. The median overall survival was 15.6 months (95% CI, 12.9 to not evaluable); estimated 6- and 12-month overall survival was 80.3% and 61.1%, respectively. Grade 3 or higher cytokine release syndrome developed in 2.4% of the patients, and grade 3 or higher immune effector cell-associated neurotoxicity syndrome developed in 7.1% of the patients. CONCLUSIONS: Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics; FELIX ClinicalTrials.gov number, NCT04404660.).
引用
- Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024. PMID: 39602653. doi:10.1056/NEJMoa2406526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。